NCT05673200
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05673200
Title Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
Mayo Clinic Hospital in Arizona RECRUITING Phoenix Arizona 85054 United States Details
UC Irvine Health Cancer Center-Newport RECRUITING Costa Mesa California 92627 United States Details
UC Irvine Health/Chao Family Comprehensive Cancer Center RECRUITING Orange California 92868 United States Details
University of California Davis Comprehensive Cancer Center ACTIVE_NOT_RECRUITING Sacramento California 95817 United States Details
Mayo Clinic in Florida RECRUITING Jacksonville Florida 32224-9980 United States Details
Mayo Clinic in Rochester RECRUITING Rochester Minnesota 55905 United States Details
Ohio State University Comprehensive Cancer Center RECRUITING Columbus Ohio 43210 United States Details
University of Oklahoma Health Sciences Center RECRUITING Oklahoma City Oklahoma 73104 United States Details
University of Pittsburgh Cancer Institute (UPCI) RECRUITING Pittsburgh Pennsylvania 15232 United States Details
VCU Massey Comprehensive Cancer Center RECRUITING Richmond Virginia 23298 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field